EUVIMEDEUVIMED entdecken
Crossref

Two‐phase Bayesian latent class analysis to assess diagnostic test performance in the absence of a gold standard: COVID ‐19 serological assays as a proof of concept

Felix Camirand Lemyre iD, Sewanou Hermann Honfo, Chelsea Caya, Matthew P Cheng, Karen Colwill iD, Rachel Corsini, Anne-Claude Gingras iD, Agatha Jassem, Mel Krajden, Ana Citlali Márquez, Bruce D Mazer, Meghan McLennan iD und 4 weitere

Vox Sanguinis · 2023

DOI: 10.1111/vox.13545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, 2023. Verfasst von Felix Camirand Lemyre und 15 weiteren Autor:innen. Beteiligte Einrichtung: Faculté des sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: COVID-19 Immunity Task Force (CITF), Public Health Agency of Canada (PHAC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives In this proof‐of‐concept study, which included blood donor samples, we aimed to demonstrate how Bayesian latent class models (BLCMs) could be used to estimate SARS‐CoV‐2 seroprevalence in the absence of a gold standard assay under a two‐phase sampling design. Materials and Methods To this end, 6810 plasma samples from blood donors who resided in Québec (Canada) were collected from May to July 2020 and tested for anti‐SARS‐CoV‐2 antibodies using seven serological assays (five commercial and two non‐commercial).

Results

SARS‐CoV‐2 seroprevalence was estimated at 0.71% (95% credible interval [CrI] = 0.53%–0.92%). The cPass assay had the lowest sensitivity estimate (88.7%; 95% CrI = 80.6%–94.7%), while the Héma‐Québec assay had the highest (98.7%; 95% CrI = 97.0%–99.6%).

Conclusion

The estimated low seroprevalence (which indicates a relatively limited spread of SARS‐CoV‐2 in Quebec) might change rapidly—and this tool, developed using blood donors, could enable a rapid update of the prevalence estimate in the absence of a gold standard. Further, the present analysis illustrates how a two‐stage BLCM sampling design, along with blood donor samples, can be used to estimate the performance of new diagnostic tests and inform public health decisions regarding a new or emerging disease for which a perfect reference standard does not exist.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSARS-CoV-2Latent Class AnalysisBayes TheoremSeroepidemiologic StudiesSensitivity and SpecificityAntibodies, ViralDiagnostic Tests, RoutineCOVID-19 Testing

Stichwörter der Autor:innen

Bayesian latent class analysisCOVID-19 serological testingSARS-CoV-2blood donorsdiagnostic accuracyseroprevalence

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Faculté des sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
  • Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.
  • Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
  • McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Quebec, Canada.
  • Division of Microbiology, Department of Clinical Laboratory Medicine, Optilab Montreal - McGill University Health Centre, Montreal, Quebec, Canada.
  • Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.

ORCID-Profile: Felix Camirand Lemyre, Karen Colwill, Anne-Claude Gingras, Meghan McLennan, Antoine Lewin

Förderung

  • COVID-19 Immunity Task Force (CITF)
  • Public Health Agency of Canada (PHAC)

Zitieren

APA

Camirand Lemyre, F., Honfo, S. H., Caya, C., Cheng, M. P., Colwill, K., Corsini, R., Gingras, A. C., Jassem, A., Krajden, M., Márquez, A. C., Mazer, B. D., McLennan, M., Renaud, C., Yansouni, C. P., Papenburg, J., & Lewin, A. (2023). Two‐phase Bayesian latent class analysis to assess diagnostic test performance in the absence of a gold standard: COVID ‐19 serological assays as a proof of concept. Vox Sanguinis. https://doi.org/10.1111/vox.13545

Vancouver

Camirand Lemyre F, Honfo SH, Caya C, Cheng MP, Colwill K, Corsini R, et al. Two‐phase Bayesian latent class analysis to assess diagnostic test performance in the absence of a gold standard: COVID ‐19 serological assays as a proof of concept. Vox Sanguinis. 2023. doi:10.1111/vox.13545

BibTeX
@article{CamirandLemyre2023,
  author = {Camirand Lemyre, Felix and Honfo, Sewanou Hermann and Caya, Chelsea and Cheng, Matthew P and Colwill, Karen and Corsini, Rachel and Gingras, Anne-Claude and Jassem, Agatha and Krajden, Mel and Márquez, Ana Citlali and Mazer, Bruce D and McLennan, Meghan and Renaud, Christian and Yansouni, Cedric P and Papenburg, Jesse and Lewin, Antoine},
  title = {Two‐phase Bayesian latent class analysis to assess diagnostic test performance in the absence of a gold standard: COVID ‐19 serological assays as a proof of concept},
  journal = {Vox Sanguinis},
  year = {2023},
  doi = {10.1111/vox.13545}
}
Kostenlos starten →